Breast cancer is a common malignant tumor in women, and it is also an endocrine-related disease, so doctors standardize and individualize the treatment according to the early and late stage of the disease and the molecular typing of the lesions. In order to get the correct treatment, doctors attach great importance to the pathological re-testing of recurrent and metastatic breast cancer, which requires the cooperation of patients. Recurrent metastases include local recurrence such as chest wall recurrence, contralateral breast recurrence, axillary or supraclavicular lymph node recurrence, subcutaneous nodes, etc., while distant metastases include bone, liver, lung, pleura, brain, etc. If the recurrent metastases are inconsistent with the ER, PR and HER2 of the primary foci, the treatment plan should be adjusted. If the primary foci are ER positive but the metastases are negative, the original endocrine therapy may need to be changed to chemotherapy, if the primary foci are ER negative but the metastases are positive, then endocrine therapy can be tried; if the primary foci are HER2 negative but the metastases are positive, then Herceptin targeted therapy is recommended, if the primary foci are HER2 positive but the metastases are negative, should Herceptin continue to be applied? Need to consider cost-effective more consultation with doctors.